NCR300 / Nuwacell Biotech - LARVOL DELTA

A Study on Efficacy and Safety of iNK Cells for CAEBV /EBV-HLH After Allo-HSCT (clinicaltrials.gov) - P=N/A | N=15 | Not yet recruiting | Sponsor: Beijing Friendship Hospital

New trial • Bone Marrow Transplantation • Epstein-Barr Virus Infections • Immunology • Infectious Disease • Rare Diseases • Transplantation

A Trial to Evaluate the Safety and Efficacy of NCR300 in Preventing Recurrence of Acute Myeloid Leukemia（AML) After Transplantation (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd.

New P1 trial • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Oncology • Transplantation

Zhongsheng’s traceable iPSC-derived NK cell drug IND has been accepted [Google translation] (Bioon.com) - "On August 23, the CDE official website announced that Anhui Zhongsheng Traceability Biotechnology Co., Ltd...'NCR300 Injection' IND application has been accepted, and this clinical application is a new indication application. On April 20 this year, Zhongsheng Traceable's 'NCR300 Injection' was approved for clinical use, and plans to carry out clinical trials for myelodysplastic syndrome (MDS), becoming the first iPSC-derived iNK therapy approved for clinical use in China....NCR300 Injection' is an iNK product manufactured by Zhongsheng Suyuan in industrialized and large-scale production under the drug cGMP standard. It can be used in the clinical treatment of various malignant tumors and improve the efficiency and stability of cell therapy."

New trial • Hematological Malignancies • Myelodysplastic Syndrome • Oncology

A Trial to Evaluate the Safety and Efficacy of NK Cells in Subjects With Myelodysplastic Syndromes (clinicaltrials.gov) - P1 | N=15 | Not yet recruiting | Sponsor: Nuwacell Biotechnologies Co., Ltd.

New P1 trial • Hematological Malignancies • Myelodysplastic Syndrome • Oncology